Isosorbide-2-carbamate esters: Potent and selective butyrylcholinesterase inhibitors

Journal of Medicinal Chemistry

Volumn 51, Issue 20, 2008, Pages 6400-6409

  Carolan, Ciaran G ^a   Dillon, Gerald P ^a   Gaynor, Joanne M ^b   Reidy, Sean ^b   Ryder, Sheila A ^a   Khan, Denise ^a   Marquez, Juan F ^a   Gilmer, John F ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b Athletic Rehabilitation Therapy Ireland   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

2 (BENZYLAMINOCARBONYLOXY) 5 O (1 NAPHTHOYL) 1,4:3,6 DIANHYDRO DEXTRO GLUCITOL; ACETYLCHOLINESTERASE; ALKYL GROUP; CARBAMIC ACID DERIVATIVE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; ESTER DERIVATIVE; ISOSORBIDE 2 (BENZYLCARBAMATE) 5 BENZOATE; ISOSORBIDE 2 (BENZYLCARBAMATE) 5 MONONITRATE; ISOSORBIDE 2 (BUTYLCARBAMATE) 5 BENZOATE; ISOSORBIDE 2 (BUTYLCARBAMATE) 5 MONONITRATE; ISOSORBIDE 2 (METHYLCARBAMATE) 5 BENZOATE; ISOSORBIDE 2 BENZYLCARBAMATE; ISOSORBIDE 2 BENZYLCARBAMATE 5 BENZOATE; ISOSORBIDE 2 BENZYLCARBAMATE 5 CYCLOPENTANOATE; ISOSORBIDE 2 BENZYLCARBAMATE 5 CYCLOPROPANOATE; ISOSORBIDE 2 BENZYLCARBAMATE 5 NICOTINATE; ISOSORBIDE 2 CARBAMATE ESTER DERIVATIVE; ISOSORBIDE 2 PHENYLCARBAMATE 5 MONONITRATE; ISOSORBIDE MONONITRATE; NITRIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CARBAMOYLATION; CHEMICAL REACTION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; IC 50; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

BINDING SITES; BUTYRYLCHOLINESTERASE; CARBAMATES; CHOLINESTERASE INHIBITORS; ESTERS; HUMANS; ISOSORBIDE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 54549109078     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800564y     Document Type: Article

References (41)

1. Francis, P. T.; Palmer, A. M.; Snape, M.; Wilcock, G. K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry 1999, 66, 137-147.
2. Bartus, R. T.; Dean, R. L.; Beer, B.; Lippa, A. S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217, 408-417.
3. Drachman, D. A.; Leavitt, J. Human memory and the cholinergic system. Arch. Neurol. 1974, 30, 113-121.
4. Muñoz-Ruiz, P.; Rubio, L.; García-Palomero, E.; Dorronsoro, I.; del Monte-Millán, M.; Valenzuela, R.; Usán, P.; de Austria, C.; Bartolini, M.; risano, V.; Bidon-Chanal, A.; Orozco, M.; Luque, F. J.; Medina, M.; Martínez, A. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease. J. Med. Chem. 2005, 48, 7223-7233.
5. Bolognesi, M. L.; Cavalli, A.; Valgimigli, L.; Bartolini, M.; Rosini, M.; risano, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease. J. Med. Chem. 2007, 50, 6446-6449.
6. Camps, P.; Formosa, X.; Muñoz-Torrero, D.; Petrignet, J.; Badia, A.; Clos, M. V. Synthesis and pharmacological evaluation of huprinetacrine heterodimers: subnanomolar dual binding site acetylcholinesterase inhibitors. J. Med. Chem. 2005, 48, 1701-1704.
7. Elsinghorst, P. W.; Cieslik, J. S.; Mohr, K.; Tränkle, C.; Gütschow, M. First gallamine-tacrine hybrid: design and characterization at cholinesterases and the M2 muscarinic receptor. J. Med. Chem. 2007, 50, 5685-5695.
8. Brühlmann, C.; Ooms, F.; Carrupt, P. A.; Testa, B.; Catto, M.; Leonetti, F.; Altomare, C.; Carotti, A. Coumarins derivatives as dual inhibitors of acetylcholinesterase and monoamine oxidase. J. Med. Chem. 2001, 44, 3195-3198.
9. Rodríguez-Franco, M. I.; Fernández-Bachiller, M. I.; Pérez, C.; Hernández-Ledesma, B.; Bartolomé, B. Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. J. Med. Chem. 2006, 49, 459-462.
10. Fang, L.; Appenroth, D.; Decker, M.; Kiehntopf, M.; Roegler, C.; Deufel, T.; Fleck, C.; Peng, S.; Zhang, Y.; Lehmann, J. Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates. J. Med. Chem. 2008, 51, 713-716.
11. Iwasaki, T.; Yoneda, M.; Nakajima, A.; Terauchi, Y. Serum butyrylcholinesterase is strongly associated with adiposity, the serum lipid profile and insulin resistance. Intern. Med. 2007, 46, 1633-1639.
12. Mesulam, M. M.; Guillozet, A.; Shaw, P.; Levey, A.; Duysen, E. G.; Lockridge, O. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 2002, 110, 627-639.
13. Perry, E. K.; Perry, R. H.; Blessed, G.; Tomlinson, B. E. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol. Appl. Neurobiol. 1978, 4, 273-277.
14. Guillozet, A. L.; Smiley, J. F.; Mash, D. C.; Mesulam, M. M. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann. Neurol. 1997, 42, 909-918.
15. Greig, N. H.; Utsuki, T.; Ingram, D. K.; Wang, Y.; Pepeu, G.; Scali, C.; Yu, Q. S.; Mamczarz, J.; Holloway, H. W.; Giordano, T.; Chen, D.; Furukawa, K.; Sambamurti, K.; Brossi, A.; Lahiri, D. K. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning, and lowers Alzheimer beta-amyloid peptide in rodent. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 17213-17218.
16. Gilmer, J. F.; Moriarty, L. M.; McCafferty, D. F.; Clancy, J. M. Synthesis, hydrolysis kinetics and antiplatelet effects of isosorbide mononitrate derivatives of aspirin. Eur. J. Pharm. Sci 2001, 14, 221-227.
17. Gilmer, J. F.; Moriarty, L. M.; Lally, M. N.; Clancy, J. M. Isosorbide-based aspirin prodrugs. II. Hydrolysis kinetics of isosorbide diaspirinate. Eur. J. Pharm. Sci. 2002, 16, 297-304.
18. Gilmer, J. F.; Lally, M. N.; Gardiner, P.; Dillon, G.; Gaynor, J. M.; Reidy, S. Novel isosorbide-based substrates for human butyrylcholinesterase. Chem. Biol. Interact. 2005, 157-158, 317-319.
19. Ellman, G. L.; Courtney, K. D.; Andres, V.; Featherstone, R. M. A New and Rapid Colorimetric Determination of Acetylcholinesterase Activity. Biochem. Pharmacol. 1961, 7, 88-95.
20. Groner, E.; Ashani, Y.; Schorer-Apelbaum, D.; Sterling, J.; Herzig, Y.; Weinstock, M. The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates. Mol. Pharmacol. 2007, 71, 1610-1617.
21. Bartolucci, C.; Siotto, M.; Ghidini, E.; Amari, G.; Bolzoni, P. T.; Racchi, M.; Villetti, G.; Delcanale, M.; Lamba, D. Structural determinants of Torpedo californica acetylcholinesterase inhibition by the novel and orally active carbamate based anti-Alzheimer drug ganstigmine (CHF-2819). J. Med. Chem. 2006, 49, 5051-5058.
22. Luo, W.; Yu, Q. S.; Zhan, M.; Parrish, D.; Deschamps, J. R.; Kulkarni, S. S.; Holloway, H. W.: Alley, G. M.; Lahiri, D. K.; Brossi, A. Novel anticholinesterases based on the molecular skeletons of furobenzofuran and methanobenzodioxepine. J. Med. Chem. 2005, 48, 986-994.
23. Yu, Q.; Holloway, H. W.; Utsuki, T.; Brossi, A.; Greig, N. H. Synthesis of Novel Phenserine-Based-Selective Inhibitors of Butyrylcholinesterase for Alzheimer's Disease. J. Med. Chem. 1999, 42, 1855-1861.
24. Saxena, A.; Redman, A. M.; Jiang, X.; Lockridge, O.; Doctor, B. P. Differences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase. Biochemistry 1997, 36, 14642-14651.
25. Carolan, C. G.; Gaynor, J. M.; Dillon, G. P.; Khan, D.; Ryder, S.; Reidy, S. A.; Gilmer, J. F. Novel isosorbide di-ester compounds as inhibitors of acetylcholinesterase. Chem-Biol. Interact. 2008, 18606399. [Epub ahead of print], PMID.
26. Li, B.; Sedlacek, M.; Manoharan, I.; Boopathy, R.; Duysen, E. G.; Masson, P.; Lockridge, O. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem. Pharmacol. 2005, 70, 1673-1684.
27. Khan, D.; Gilmer, J. F.; Carolan, C. G.; Gaynor, J. M.; Ryder, S. A. Pharmacological effects of a novel isosorbide-based butyrylcholinesterase inhibitor. Chem.-Biol. Interact. 2008, 18606399. [Epub ahead of print] PMID.
28. Harel, M.; Kleywegt, G. J.; Ravelli, R. B.; Silman, I.; Sussman, J. L. Crystal structure of an acetylcholinesterase-fasciculin complex: interaction of a three-fingered toxin from snake venom with its target. Structure 1995, 3, 1355-1366.
29. Harel, M.; Quinn, D. M.; Nair, H. K.; Silman, I.; Sussman, J. L. The X-ray Structure of a Transition State Analog Complex Reveals the Molecular Origins of the Catalytic Power and Substrate Specificity of Acetylcholinesterase. J. Am. Chem. Soc. 1996, 188, 2340-2346.
30. Harel, M.; Schalk, I.; Ehret-Sabatier, L.; Bouet, F.; Goeldner, M.; Hirth, C.; Axelsen, P. H.; Silman, I.; Sussman, J. L. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 9031-9035.
31. Sussman, J. L.; Harel, M.; Frolow, F.; Oefner, C.; Goldman, A.; Toker, L.; Silman, I. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 1991, 253, 872-879.
32. Nicolet, Y.; Lockridge, O.; Masson, P.; Fontecilla-Camps, J. C.; Nachon, F. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J. Biol. Chem. 2003, 278, 41141-41147.
33. Gao, D.; Zhan, C. G. Modeling effects of oxyanion hole on the ester hydrolysis catalyzed by human cholinesterases. J. Phys. Chem. B 2005, 109, 23070-23076.
34. Luo, W.; Yu, Q. S.; Kulkarni, S. S.; Parrish, D. A.; Holloway, H. W.; Tweedie, D.; Shafferman, A.; Lahiri, D. K.; Brossi, A.; Greig, N. H. Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. J. Med. Chem. 2006, 49, 2174-2185.
35. Bar-On, P. M. C.; Harel, M.; Dvir, H.; Enz, A.; Sussman, J. L.; Silman, I. Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine. Biochemistry 2002, 41, 3555-3564.
36. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.
37. Halgren, T. A. Merck molecular force field 0.1. Basis, form, scope, parameterization, and performance of MMFF94. J. Comput. Chem. 1996, 17, 490-519.
38. Halgren, T. A. MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular-interaction energies and geometries. J. Comput. Chem. 1999, 20, 730-748.
39. Jakalian, A.; Bush, B. L.; Jack, D. B.; Bayly, C. I. Fast, efficient generation of high-quality atomic charges. AM1-BCC model: I. Method. J. Comput. Chem. 2000, 21, 132-146.
40. Dolinsky, T. J.; Nielsen, J. E.; McCammon, J. A.; Baker, N. A. PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res. 2004, 32, W665-W667.
41. a values. Proteins 2005, 61, 704-721.